Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing a disease control rate (DCR) of 49.3% [2][3] - Notable clinical activity included reductions in tumor-specific biomarkers, long-term stable disease, and a confirmed partial response in a patient with micro-satellite stable colorectal cancer [2][3] - The most significant reductions in prostate-specific antigen (PSA) were observed in patients receiving BID dosing, with 6 out of 13 patients achieving PSA reductions of ≥50% [2] Safety Profile - NX-1607 exhibited a tolerable safety profile, comparable to approved immuno-oncology agents, with most adverse events being Grade 2 or less [3] - Immune-related adverse events were observed in 6 patients, indicating on-target immune activation similar to PD-1/PD-L1 therapies [3] Future Development - The company plans to further explore the therapeutic potential of NX-1607, particularly in indications where current immunotherapies have shown limited efficacy, such as MSS colorectal cancer and metastatic prostate cancer [4]